Shire PLC

from Wikipedia, the free encyclopedia
Shire PLC

logo
legal form Public Limited Company
ISIN JE00B2QKY057
founding 1986
Seat Saint Helier , Jersey
management Flemming Ornskov
( CEO )
Susan Kilsby
( Chair )
Number of employees 23,906 (December 31, 2016)
sales 11.4 billion US dollars (2016)
Branch pharmacy
Website www.shire.com
As of December 31, 2016

Shire PLC was founded in 1986 pharmaceutical companies with legally established in Saint Helier on Jersey and operational seats in the Irish Dublin and in British Hampshire . In early January 2019, Shire announced that the Japanese pharmaceutical company Takeda had completed the acquisition of Shire .

history

At the beginning of the company's history, Shire sold calcium supplements (Calcichew) for the treatment of osteoporosis and other bone diseases under the then name AimCane . Through worldwide mergers , acquisitions and distributions , Shire has branches in the United States , Canada , Ireland , France , Germany , Italy and Spain . In 2008, the German listed company Jerini and with it the preparation Firazyr were taken over. In January 2014 Shire acquired the US pharmaceutical company ViroPharm , which was previously traded on the NASDAQ , and thus u. a. also taken over the epilepsy product Buccolam ( midazolam ). In July 2014, Shire agreed to a takeover by the US pharmaceutical company AbbVie . In the course of the negotiations, however, AbbVie withdrew its offer. In January 2015, Shire acquired the US pharmaceutical company NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), which had previously also been traded on the NASDAQ.

Baxalta

In August 2015, Shire plc made an offer of approximately $ 30.6 billion in US biotechnology company Baxalta , which was later increased to approximately $ 32 billion and was accepted in January 2016. Baxalta itself was formed in July 2015 spin (spin-off) , the Biotechnology Division of Baxter International . Baxalta had sales of approximately $ 6 billion in drugs to treat hemophilia and other blood clotting disorders, immune deficiencies , intraoperative wound care, and the development of certain vaccines for rare diseases.

In June 2016, was the fusion of the two companies completed plc for Shire, which Shire plc as a world leader in the field of rare and complex diseases ( orphan diseases ) was.

Acquisition by Takeda

In July 2018, it was announced that the largest Japanese pharmaceutical company, Takeda, intends to buy Shire for $ 62 billion. Various permits are required before this acquisition is possible. A first hurdle is the "Clearance" of the United States Federal Trade Commission that took place in July 2018 . Further approvals from regulatory authorities in China and the European Union are still pending; the shareholders of both parties still have to be convinced. If this acquisition were successful, Takeda would be among the 10 largest pharmaceutical companies in the world.

In early January 2019, Shire announced that Takeda had completed the acquisition of Shire.

Acquisition of the oncology division by Servier

At the end of August 2018, Servier took over Shire's international oncology business.

Indication areas

Shire offers special preparations in the following areas of indication (the corresponding preparations are behind in the brackets):

Other preparations

Other preparations include: Dermagraft (for the treatment of diabetic foot syndrome )

Web links

Individual evidence

  1. ^ Shire: Shire Corporate History . 2014. Retrieved February 14, 2014.
  2. ↑ Shire: Shire Board of Directors . 2014. Retrieved February 14, 2014.
  3. ↑ a b Annual Report 2016 . Shire plc, accessed November 13, 2017 (PDF; 7.7 MB; English).
  4. ↑ a b Takeda Completes Acquisition of Shire, Becoming a Global, Values-based, R & D-Driven Biopharmaceutical Leader PM Shire, January 8, 2019, accessed January 11, 2019
  5. ↑ Annual Report 2011 ( Memento of February 2, 2013 in the web archive archive.today ), Shire head offices and main operating locations
  6. ↑ Shire waives OFT condition relating to the acquisition of ViroPharma Inc. , PM Shire plc, January 15, 2014, accessed December 8, 2014.
  7. ↑ Shire agrees to Abbvie's billion dollar offer , Handelsblatt July 18, 2014, accessed December 8, 2014.
  8. ↑ AbbVie pays billions in severance payments for a failed deal , Handelsblatt of October 21, 2014, accessed on December 8, 2014.
  9. ↑ Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech , PM Shire plc, January 11, 2015, accessed January 11, 2015.
  10. ↑ a b SHIRE TO COMBINE WITH BAXALTA, CREATING THE GLOBAL LEADER IN RARE DISEA SES , PM Shire, January 11, 2016, accessed January 11, 2016
  11. ↑ Shire merges with Baxalta and becomes the market leader in rare and complex diseases . Shire plc press release on finanzen.net, June 3, 2016, accessed November 13, 2017.
  12. ↑ Pharmaceutical company Takeda receives US approval for Shire takeover , Börse-online on July 10, 2018, accessed on September 5, 2018
  13. ↑ Servier finalizes acquisition of Shire's oncology branch ; PM Servier, August 31, 2018, accessed September 5, 2018
  14. ↑ Servier Completes Acquisition of Shire Oncologics ; Doctors' newspaper of September 3, 2018, accessed on September 5, 2018
  15. ↑ Shire sells cancer drugs to Servier for $ 2.4 billion as Takeda circles , Reuters April 16, 2018, accessed September 5, 2018